• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮质类固醇在脑脊液中的渗透差异:与预防脑膜白血病的可能关系。

Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.

作者信息

Balis F M, Lester C M, Chrousos G P, Heideman R L, Poplack D G

出版信息

J Clin Oncol. 1987 Feb;5(2):202-7. doi: 10.1200/JCO.1987.5.2.202.

DOI:10.1200/JCO.1987.5.2.202
PMID:3806166
Abstract

The disposition of the synthetic corticosteroids, dexamethasone and prednisolone, in CSF was evaluated following bolus intravenous (IV) and intrathecal (IT) injection in a nonhuman primate model. Steroid concentration in plasma and CSF was measured with a radioimmunoassay following celite column chromatography. The CSF to plasma ratios of dexamethasone and prednisolone following IV bolus administration were 0.15 +/- 0.02 and 0.08 +/- 0.03, respectively. Although peak levels of the two steroids in the CSF reached equally potent levels when administered systemically in equipotent doses, the half-life of prednisolone in the CSF was shorter. In addition, there was a significant difference in the plasma protein binding of the two steroids, which may account for the differences in their CSF pharmacokinetics. Dexamethasone was 70% protein bound over a wide concentration range, while the protein binding of prednisolone was concentration dependent, ranging from 60% at 10 mumol/L to 95% at 0.5 mumol/L and below. After the initial distribution phase in plasma, CSF concentrations of dexamethasone and prednisolone approximated free plasma concentrations, indicating that penetration into the CSF was limited primarily by protein binding. At the plasma concentrations achieved following oral administration of standard doses of prednisone in children, the prednisolone (the active metabolite) is greater than 90% protein bound. The proportionally higher free plasma levels of dexamethasone result in greater penetration into the CSF. These findings may explain the lower rates of meningeal leukemia observed in children receiving dexamethasone instead of prednisone for the treatment of acute lymphoblastic leukemia (ALL).

摘要

在非人类灵长类动物模型中,通过静脉推注(IV)和鞘内注射(IT),评估了合成皮质类固醇地塞米松和泼尼松龙在脑脊液中的分布情况。在硅藻土柱色谱分离后,采用放射免疫分析法测定血浆和脑脊液中的类固醇浓度。静脉推注给药后,地塞米松和泼尼松龙的脑脊液与血浆比值分别为0.15±0.02和0.08±0.03。尽管以等效剂量全身给药时,脑脊液中这两种类固醇的峰值水平达到同等效力,但泼尼松龙在脑脊液中的半衰期较短。此外,这两种类固醇的血浆蛋白结合存在显著差异,这可能解释了它们在脑脊液药代动力学方面的差异。地塞米松在较宽的浓度范围内有70%与蛋白结合,而泼尼松龙的蛋白结合呈浓度依赖性,在10 μmol/L时为60%,在0.5 μmol/L及以下时为95%。在血浆中的初始分布阶段后,地塞米松和泼尼松龙的脑脊液浓度接近游离血浆浓度,表明进入脑脊液的渗透主要受蛋白结合限制。在儿童口服标准剂量泼尼松后达到的血浆浓度下,泼尼松龙(活性代谢物)与蛋白结合率大于90%。地塞米松相对较高的游离血浆水平导致其进入脑脊液的渗透更多。这些发现可能解释了在治疗急性淋巴细胞白血病(ALL)时,接受地塞米松而非泼尼松治疗的儿童中脑膜白血病发生率较低的原因。

相似文献

1
Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.皮质类固醇在脑脊液中的渗透差异:与预防脑膜白血病的可能关系。
J Clin Oncol. 1987 Feb;5(2):202-7. doi: 10.1200/JCO.1987.5.2.202.
2
Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.脑室注射和静脉注射氮丙啶基苯醌的脑脊液药代动力学
Cancer Res. 1984 Apr;44(4):1698-701.
3
Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.急性淋巴细胞白血病患儿中泼尼松龙的群体药代动力学
Cancer Chemother Pharmacol. 2003 Jun;51(6):465-73. doi: 10.1007/s00280-003-0602-3. Epub 2003 Apr 16.
4
Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.柔红霉素、伊达比星及其代谢产物在非人灵长类动物模型中的药代动力学及脑脊液穿透情况
J Pediatr Hematol Oncol. 1999 Jan-Feb;21(1):26-30.
5
Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.长春新碱在人体脑脊液中的药代动力学。
Cancer Res. 1981 Apr;41(4):1466-8.
6
Dose dependent pharmacokinetics of prednisone and prednisolone in man.泼尼松和泼尼松龙在人体中的剂量依赖性药代动力学。
J Pharmacokinet Biopharm. 1981 Aug;9(4):389-417. doi: 10.1007/BF01060885.
7
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.恒河猴和人类脑脊液中L-天冬酰胺酶的药代动力学及天冬酰胺水平
Cancer Res. 1981 Nov;41(11 Pt 1):4554-8.
8
The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.在非人灵长类动物静脉注射厄洛替尼后,厄洛替尼及其活性代谢物(OSI-420)的血浆和脑脊液药代动力学。
Cancer Chemother Pharmacol. 2008 Aug;62(3):387-92. doi: 10.1007/s00280-007-0616-3. Epub 2007 Oct 12.
9
Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.
Cancer Chemother Pharmacol. 2001;47(1):41-4. doi: 10.1007/s002800000188.
10
Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate.非人灵长类动物鞘内注射O6-苄基鸟嘌呤后,血浆和脑脊液中O6-苄基鸟嘌呤及其活性代谢产物8-氧代-O6-苄基鸟嘌呤的药代动力学。
Clin Cancer Res. 1998 Nov;4(11):2891-4.

引用本文的文献

1
Efficacy of dexamethasone combined with intravenous immunoglobulin for the treatment of pediatric autoimmune encephalitis.地塞米松联合静脉注射免疫球蛋白治疗小儿自身免疫性脑炎的疗效
Front Neurol. 2025 Mar 12;16:1512908. doi: 10.3389/fneur.2025.1512908. eCollection 2025.
2
Hemophagocytic Lymphohistiocytosis Due to Ehrlichiosis: A Case Series.埃立克体病所致噬血细胞性淋巴组织细胞增生症:病例系列
HCA Healthc J Med. 2024 Dec 1;5(6):701-706. doi: 10.36518/2689-0216.1639. eCollection 2024.
3
Molecular, Pathophysiological, and Clinical Aspects of Corticosteroid-Induced Neuropsychiatric Effects: From Bench to Bedside.
皮质类固醇诱导的神经精神效应的分子、病理生理及临床方面:从实验台到病床
Biomedicines. 2024 Sep 19;12(9):2131. doi: 10.3390/biomedicines12092131.
4
Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan.40 岁以下新诊断为朗格汉斯细胞组织细胞增生症的儿童和成人的 II 期研究:日本 LCH-19-MSMFB 临床试验方案。
BMJ Open. 2024 Jun 23;14(6):e084159. doi: 10.1136/bmjopen-2024-084159.
5
Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection.糖皮质激素治疗急性淋巴细胞白血病:短期和长期效应的探讨以及最佳方案的选择。
Curr Hematol Malig Rep. 2024 Aug;19(4):175-185. doi: 10.1007/s11899-024-00735-w. Epub 2024 Jun 13.
6
Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.中低收入国家儿童急性淋巴细胞白血病的诊断和治疗策略。
Leukemia. 2024 Aug;38(8):1649-1662. doi: 10.1038/s41375-024-02277-9. Epub 2024 May 18.
7
Dengue-Associated Hemophagocytic Lymphohistiocytosis: A Narrative Review of Its Identification and Treatment.登革热相关噬血细胞性淋巴组织细胞增生症:关于其识别与治疗的叙述性综述
Pathogens. 2024 Apr 17;13(4):332. doi: 10.3390/pathogens13040332.
8
Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective.儿童急性淋巴细胞白血病的治疗:历史视角
Cancers (Basel). 2024 Feb 8;16(4):723. doi: 10.3390/cancers16040723.
9
Dexamethasone versus methylprednisolone for multiple organ dysfunction in COVID-19 critically ill patients: a multicenter propensity score matching study.地塞米松与甲泼尼龙治疗 COVID-19 危重症患者多器官功能障碍:一项多中心倾向评分匹配研究。
BMC Infect Dis. 2024 Feb 13;24(1):189. doi: 10.1186/s12879-024-09056-y.
10
Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.比较地塞米松、德氟拉松和万莫罗龙在 DMD 疾病模型中的药物特性和生物学活性。
Hum Mol Genet. 2024 Jan 20;33(3):211-223. doi: 10.1093/hmg/ddad173.